This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's ETF Winners & Losers

The HealthShares Emerging Cancer (HHJ) exchange-traded fund was one of the best performers during Tuesday's abbreviated session, thanks to a nearly 10% surge in shares of Dendreon (DNDN).

Traders expect that Dendreon will announce positive news on its prostate cancer drug, sending the stock up 68 cents to $7.91. The HealthShares Emerging Cancer ETF was recently adding 30 cents, or 1.4%, to $21.90.

The iShares Dow Jones U.S. Broker-Dealer (IAI) was also gaining ground, thanks to holdings Morgan Stanley (MS), Merrill Lynch (MER), Goldman Sachs (GS) and Bear Stearns (BSC), all of which were higher by 1% or more.

The Broker-Dealer ETF was recently up 66 cents, or 1.2%, to $55.93.

Meanwhile, shares of Apple (AAPL - Get Report) jumped more than 4%, powering the Internet Architecture HOLDRs (IAH) higher. Apple's new iPhone should deliver profit margins of 55% on the $600 eight gigabyte version, according to iSuppli. The ETF was rising by 49 cents, or 1%, to $48.18.

On the other hand, bundled securities tracking silver and gold were among the worst performers. Silver futures fell by 4 cents to $12.64 an ounce. Gold futures was losing $4.20 to $655 an ounce

The PowerShares DB Silver (DBS) was down 24 cents, or 1%, to $24.69. The iShares Silver Trust (SLV) was down 97 cents, or 0.8%, to $124.91. The PowerShares DB Gold (DGL) eased 20 cents, or 0.8%, to $25.80. The PowerShares DB Precious Metals (DBP) shed 17 cents, or 0.7%, to $25.54.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DBS $27.82 1.42%
DBP $39.51 0.77%
DGL $42.16 0.91%
IAI $36.70 -0.90%
SLV $16.63 0.73%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs